New Jersey’s controlled substance prescription requirements combine federal DEA rules with a stricter state layer: prescribers need both a DEA registration and a separate New Jersey Controlled Dangerous Substances (CDS) registration, must issue prescriptions electronically through a DEA-compliant system, are capped at a five-day initial supply when prescribing opioids for acute pain, and must query the state Prescription Monitoring Program at specific trigger points. Pharmacists carry their own reporting and verification duties. Miss any of these and the consequences run from board discipline to criminal charges.
Who Can Prescribe
Two registrations are required before a single controlled substance prescription can be written in New Jersey. The federal DEA registration comes first, and the New Jersey CDS registration is issued separately by the Division of Consumer Affairs. The address on both must match, and a DEA registration issued for another state does not carry over. Each physical location where a practitioner prescribes or dispenses needs its own registration.1New Jersey Division of Consumer Affairs. New Jersey CDS Registration Processing Questions
The CDS application fee is $40 for most practitioners, including physicians, dentists, veterinarians, and advanced practice nurses. Distributors pay $200 and manufacturers pay $400. A criminal history records check, when required, adds $20.1New Jersey Division of Consumer Affairs. New Jersey CDS Registration Processing Questions If the registration lapses, there is no online renewal and no grace period. The prescriber must file a reinstatement application and cannot legally prescribe controlled substances until it clears.
Prescribers also owe an ongoing education obligation. Every license renewal cycle requires at least one Category 1 CME credit covering responsible prescribing, alternatives to opioids for pain management, and the risks and signs of opioid abuse, addiction, and diversion.
What Drugs Fall Under These Rules
New Jersey adopts the five federal schedules by reference, incorporating 21 CFR 1308.11 through 1308.15 unless the Director of the Division of Consumer Affairs objects to a specific classification.2Cornell Law School. New Jersey Code 13:45H-10.1 – Schedules of Controlled Dangerous Substances Schedule I drugs have no accepted medical use and cannot be prescribed at all. Schedule II covers the tightest-restricted prescribable drugs, including oxycodone, fentanyl, morphine, and amphetamine. Schedule III includes buprenorphine and certain codeine combinations. Schedule IV contains the benzodiazepines such as alprazolam and diazepam. Schedule V holds preparations with small quantities of narcotics.
How Prescriptions Must Be Transmitted
Controlled substance prescriptions in New Jersey must be issued electronically through a DEA-compliant system. That system has to meet DEA standards for prescriber identity verification, including two-factor authentication, and must generate, transmit, and store prescriptions in a format that cannot be altered after signing. Pharmacies receiving the prescription need compliant software on their end to authenticate the origin and credentials.
A paper or oral prescription is allowed only when a recognized exception applies: technological failure, veterinary prescriptions, certain compounded medications, or a waiver from the Division of Consumer Affairs. When any of those apply, the prescriber must document why electronic prescribing was not used.
Initial Opioid Prescribing Limits
For acute pain, the first opioid prescription cannot exceed a five-day supply, and it must be for the lowest effective dose of an immediate-release opioid. Before writing that first prescription, the prescriber has to discuss the risks and benefits of opioid treatment and available alternatives with the patient.3New Jersey Division of Consumer Affairs. Prescribing Opioids in New Jersey
A second prescription may follow, but no sooner than four days after the first, and only after the prescriber personally consults with the patient. A phone call is enough; a conversation handled by office staff is not. The prescriber must document the reason additional supply is appropriate and confirm it does not create an undue risk of abuse, addiction, or diversion.4NJ Consumer Affairs / Board of Medical Examiners. Frequently Asked Questions for Practitioners Licensed by the Board of Medical Examiners
For chronic pain, defined as pain lasting more than three months, the risks-and-alternatives discussion must be repeated at least every three months for as long as the patient stays on opioids.
Who Is Exempt From the Five-Day Cap
The initial prescribing restrictions do not apply to patients in active treatment for cancer, receiving hospice care from a licensed hospice, receiving palliative care, or residing in a long-term care facility.5Cornell Law School. New Jersey Administrative Code 13:38-2.5 Medications used to treat substance use disorder or opioid dependence are exempt, as are medications administered under inpatient facility medication orders.3New Jersey Division of Consumer Affairs. Prescribing Opioids in New Jersey
Refills and Partial Fills
Schedule II prescriptions cannot be refilled. Every dispensing requires a new prescription and a fresh evaluation of the patient. That is a hard federal rule with no exceptions.
Schedule III and IV prescriptions may be refilled up to five times within six months of the original issue date. After six months, any remaining refills expire and a new prescription is needed.6eCFR. 21 CFR Part 1306 – Controlled Substances Listed in Schedules III, IV, and V Schedule V generally follows less restrictive refill rules, since the federal five-refill, six-month cap applies specifically to Schedules III and IV.
Partial fills of a Schedule II prescription follow two different clocks. If the pharmacy simply cannot supply the full quantity, the remaining portion may be dispensed within 72 hours; miss that window and the pharmacist must notify the prescriber, and any remaining quantity requires a new prescription. If the smaller quantity was requested by the prescriber or patient, the remaining portion of a written Schedule II prescription stays valid for up to 30 days from the date written. For patients in a long-term care facility or those with a documented terminal illness, that partial-fill window extends to 60 days.7eCFR. 21 CFR 1306.13 – Partial Filling of Prescriptions
Emergency Oral Prescriptions for Schedule II
When a genuine emergency makes electronic or written prescribing infeasible, a prescriber can authorize a Schedule II drug by phone. The pharmacist must immediately reduce the oral order to writing with all information normally required on a prescription, except the prescriber’s physical signature. The quantity must be limited to what is needed for the emergency period; the emergency route is not a way to authorize a full course of treatment.8eCFR. 21 CFR Part 1306 – Controlled Substances Listed in Schedule II
The prescriber then has to deliver a written follow-up prescription to the dispensing pharmacy within seven days of the oral authorization. It must show “Authorization for Emergency Dispensing” and the date of the oral order on its face, and if mailed, it must be postmarked within the seven-day window.9New Jersey Division of Consumer Affairs. Requirements of Prescriptions – Schedule II Emergency Dispensing A pharmacist who does not know the caller must make a reasonable effort to confirm the caller is a legitimately registered practitioner before dispensing.
NJPMP Lookup and Reporting
New Jersey’s Prescription Monitoring Program tracks every controlled substance dispensed in or into the state. Both prescribers and pharmacists must register for NJPMP access, and the law makes checking the database mandatory in specific situations.
A prescriber must query the NJPMP:10Cornell Law School. New Jersey Administrative Code 13:45A-35.9 – Mandatory Look-Up
- The first time prescribing any opioid or Schedule II drug for acute or chronic pain to a new or current patient.
- The first time prescribing a benzodiazepine that falls under Schedule III or IV.
- The first time prescribing any other Schedule III or IV drug when the prescriber has reasonable belief the patient may be seeking it for something other than treating a medical condition.
- Any time a Schedule II drug is prescribed for pain in a hospital emergency department.
- Every three months from the date of the initial prescription, for as long as the patient continues to receive a Schedule II drug, any opioid for pain, or a benzodiazepine.
Pharmacies feed the database from the other side. Every dispensing of a Schedule II through V controlled substance, human growth hormone, and gabapentin must be reported to the NJPMP no later than one business day after the prescription is filled, submitted electronically through the PMP Clearinghouse in the required format.11New Jersey Division of Consumer Affairs. NJ Prescription Monitoring Program Pharmacy Reporting Requirements
Naloxone Co-Prescribing Triggers
A prescriber managing chronic pain with opioids must co-prescribe an opioid antidote such as naloxone in two situations: when the patient’s total opioid prescriptions reach 90 morphine milligram equivalents or more per day, or when the patient is concurrently obtaining both an opioid and a benzodiazepine, even if those drugs come from different prescribers. The obligation sits with the opioid prescriber, not the benzodiazepine prescriber.12New Jersey Division of Consumer Affairs. Co-Prescribing Naloxone to Patients with Heightened Risk of Opioid Overdose – FAQ for Prescribers
The co-prescribing requirement does not apply to patients actively being treated for cancer, receiving hospice or palliative care, or residing in a long-term care facility. Medications prescribed for substance use disorder treatment and medications administered under inpatient facility orders are also exempt.12New Jersey Division of Consumer Affairs. Co-Prescribing Naloxone to Patients with Heightened Risk of Opioid Overdose – FAQ for Prescribers
Documentation and Record Retention
Every controlled substance prescription must be documented in the patient’s medical record with the drug name, dosage, quantity, and the medical justification for prescribing it. The prescription itself must include the patient’s full name and address, the drug and dosage form, quantity, and directions for use.
Federal regulations require controlled substance records to be kept for a minimum of two years. The New Jersey Board of Pharmacy sets a longer floor, requiring CDS prescription records be kept for at least five years, which is the operative standard for pharmacies in the state.13New Jersey Division of Consumer Affairs. General Questions Prescribers should check their own licensing board’s rules, since some boards impose retention periods longer than the federal two-year minimum.
Telehealth
The DEA and HHS have extended the telemedicine flexibilities first put in place during the COVID-19 public health emergency through December 31, 2026. Under the extension, DEA-registered practitioners can prescribe Schedule II through V controlled substances via telehealth without a prior in-person visit, provided they meet the applicable conditions.14HHS Telehealth. Prescribing Controlled Substances via Telehealth
The federal flexibility does not relax any of New Jersey’s rules. Telehealth prescribers still have to check the NJPMP at the same trigger points, hold the required registrations, comply with the five-day initial opioid supply cap for acute pain, use a DEA-compliant electronic prescribing system, and keep complete documentation. The disciplinary and criminal exposure is the same as for in-person prescribing.
Penalties for Non-Compliance
Getting a controlled substance by fraud, forgery, or misrepresentation is a third-degree crime in New Jersey, punishable by three to five years in prison and a fine of up to $50,000.15Justia Law. New Jersey Revised Statutes 2C:35-13 – Obtaining by Fraud That $50,000 cap is an enhanced fine specific to this offense; the standard third-degree fine cap is $15,000.16Justia Law. New Jersey Revised Statutes 2C:43-3 – Fines and Restitutions Prescribing or dispensing a controlled substance without a legitimate medical purpose can also lead to criminal prosecution, license suspension or revocation, and substantial fines.
Administratively, prescribers and pharmacies that miss NJPMP checks, exceed prescribing limits, or fall short on record-keeping face civil penalties and disciplinary action from their licensing boards, with repeated violations leading to permanent license revocation. Because the Division of Consumer Affairs works with the DEA, state violations involving fraudulent prescribing or large-scale diversion can escalate to federal investigation and charges.